Last reviewed · How we verify
Moderate to severe Crohn's disease
Approved treatments
- Induction- PF-06480605 450 mg SC Q4W · Pfizer
PF-06480605 is a small molecule that targets the IL-17 pathway to treat inflammatory conditions. - tumor necrosis factor inhibitors (TNFi) · Pfizer
- Etrasimod · Pfizer
Etrasimod is an S1P receptor modulator that blocks lymphocyte egress from lymphoid organs, reducing peripheral blood lymphocytes. - TNF Inhibitor · Pfizer
- Chronic- PF-06480605 50 mg SC Q4W · Pfizer
- Velsipity · Pfizer Inc.
Etrasimod binds S1P receptors 1, 4, and 5, blocking lymphocyte egress from lymphoid organs. - Induction- PF-06480605 150 mg SC Q4W · Pfizer
PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks. - Infliximab [infliximab biosimilar 3] · Pfizer
Infliximab biosimilar 3 is a monoclonal antibody that targets tumor necrosis factor-alpha (TNF-alpha) to treat inflammatory conditions. - Chronic- PF-06480605 150 mg SC Q4W · Pfizer
- Chronic- PF-06480605 150 mg SC Q4W · Pfizer
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Moderate to severe Crohn's disease patent landscape — cliff calendar, originator estates, attackable patents
- Moderate to severe Crohn's disease treatment landscape brief
- Moderate to severe Crohn's disease treatment updates RSS
Frequently asked questions about Moderate to severe Crohn's disease
What drugs treat Moderate to severe Crohn's disease?
Tracked treatments include Induction- PF-06480605 450 mg SC Q4W, tumor necrosis factor inhibitors (TNFi), Etrasimod, TNF Inhibitor, Chronic- PF-06480605 50 mg SC Q4W, Velsipity, Induction- PF-06480605 150 mg SC Q4W, Infliximab [infliximab biosimilar 3].
What is the treatment for Moderate to severe Crohn's disease?
Standard treatment for Moderate to severe Crohn's disease includes Induction- PF-06480605 450 mg SC Q4W, tumor necrosis factor inhibitors (TNFi), Etrasimod, TNF Inhibitor, Chronic- PF-06480605 50 mg SC Q4W. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Moderate to severe Crohn's disease patent cliff · Moderate to severe Crohn's disease CI report
- Treatment: Induction- PF-06480605 450 mg SC Q4W · Pfizer
- Treatment: tumor necrosis factor inhibitors (TNFi) · Pfizer
- Treatment: Etrasimod · Pfizer
- Treatment: TNF Inhibitor · Pfizer
- Treatment: Chronic- PF-06480605 50 mg SC Q4W · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing